Adipokines and their receptors: Potential new targets in cardiovascular diseases

Future Medicinal Chemistry

Volumn 7, Issue 2, 2015, Pages 139-157

  Goncąlves, Nádia ^a   Falcaõ Pires, Inês ^a   Leite Moreira, Adelino Ferreira ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPOCYTOKINE RECEPTOR; ADIPONECTIN RECEPTOR; APELIN RECEPTOR; LEPTIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN S 100; RESISTIN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; HEART DISEASE; HEART FAILURE; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; INFLAMMATION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; CHEMISTRY; METABOLISM; PATHOLOGY;

ADIPOKINES; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, ADIPOKINE;

EID: 84923131513     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.147     Document Type: Review

References (166)

1. González-Juanatey JR, Lago Paz F, Eiras S, Teijeira-Fernández E. Adipocitocinas como nuevos marcadores de la enfermedad cardiovascular. Perspectivas fisiopatológicas y clínicas. Revista Espanõla de Cardiologiá 62(Suppl. 2), 9-16 (2009).
2. Horwich TB, Fonarow GC, Hamilton MA, Maclellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38(3), 789-795 (2001).
3. Goncalves N, Roncon-Albuquerque R Jr, Oliveira M, Quina-Rodrigues C, Lourenco AP, Leite-Moreira AF. A high-calorie diet attenuates cachexia and adipose tissue inflammation in monocrotaline-induced pulmonary hypertensive rats. Rev. Port. Cardiol. 29(3), 391-400 (2010).
4. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53(21), 1925-1932 (2009).
5. Alpert MA, Agrawal H, Aggarwal K, Kumar SA, Kumar A. Heart failure and obesity in adults: pathophysiology, clinical manifestations and management. Curr. Heart Fail. Rep,11(2), 156-165 (2014).
6. Wende AR, Young ME. APpEaLINg therapeutic target for obesity cardiomyopathy J. Mol. Cell Cardiol. 63, 165-168 (2013).
7. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care 34(Suppl. 2), S371-S379 (2011).
8. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365(9473), 1817-1820 (2005).
9. Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro-and anti-inflammatory organ. Horm. Metab. Res. 40(7), 442-445 (2008).
10. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J. Am. Soc. Echocardiogr. 22(12), 1311-1319; quiz 1417-1318 (2009).
11. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 1(2), 93-102 (2013).
12. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J. 156(1), 13-22 (2008).
13. O'dowd BF, Heiber M, Chan A et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136(1-2), 355-360 (1993).
14. Tatemoto K, Hosoya M, Habata Y et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251(2), 471-476 (1998).
15. Habata Y, Fujii R, Hosoya M et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta 1452(1), 25-35 (1999).
16. Machura E, Ziora K, Ziora D et al. Serum apelin-12 level is elevated in schoolchildren with atopic asthma. Respir. Med. 107(2), 196-201 (2013).
17. Scimia MC, Hurtado C, Ray S et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 488(7411), 394-398 (2012).
18. Chun HJ, Ali ZA, Kojima Y et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J. Clin. Invest. 118(10), 3343-3354 (2008).
19. Hosoya M, Kawamata Y, Fukusumi S et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275(28), 21061-21067 (2000).
20. Kawamata Y, Habata Y, Fukusumi S et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim. Biophys. Acta 1538(2-3), 162-171 (2001).
21. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept. 126(3), 233-240 (2005).
22. Medhurst AD, Jennings CA, Robbins MJ et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J. Neuro Chem. 84(5), 1162-1172 (2003).
23. O'carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta 1492(1), 72-80 (2000).
24. Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146(4), 1764-1771 (2005).
25. Ceylan-Isik AF, Kandadi MR, Xu X et al. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell Cardiol. 63, 4-13 (2013).
26. Ba HJ, Chen HS, Su Z et al. Associations between serum apelin-12 levels and obesity-related markers in Chinese children. PLoS One 9(1), e86577 (2014).
27. Falcao-PiRes. I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev. Port. Cardiol. 24(10), 1263-1276 (2005).
28. Karadag S, Ozturk S, Gursu M et al. The relationship between apelin and cardiac parameters in patients on peritoneal dialysis: is there a new cardiac marker BMC Nephrol 15(1), 18 (2014).
29. Falcao-PiRes. I, Ladeiras-Lopes R, Leite-Moreira AF. The apelinergic system: a promising therapeutic target. Expert Opin. Ther. Targets 14(6), 633-645 (2010).
30. Foldes G, Horkay F, Szokodi I et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun. 308(3), 480-485 (2003).
31. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq. Bras. Cardiol. 90(5), 343-349 (2008).
32. Ishida J, Hashimoto T, Hashimoto Y et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressurein vivo. J. Biol. Chem. 279(25), 26274-26279 (2004).
33. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br. J. Pharmacol. 132(6), 1255-1260 (2001).
34. Andersen CU, Hilberg O, Mellemkjaer S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulm. Circ. 1(3), 334-346 (2011).
35. Zhang J, Ren CX, Qi YF et al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 79(12), 1153-1159 (2006).
36. Barnes GD, Alam S, Carter G et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ. Heart Fail. 6(3), 482-491 (2013).
37. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277(17), 14838-14843 (2002).
38. Sato T, Suzuki T, Watanabe H et al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 123(12), 5203-5211 (2013).
39. Kazemi-Bajestani SM, Patel VB, Wang W, Oudit GY. Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges. Cardiol. Res. Pract. 2012, 823193 (2012).
40. Reaux A, De Mota N, Skultetyova I et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neuro Chem. 77(4), 1085-1096 (2001).
41. Szokodi I, Tavi P, Foldes G et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 91(5), 434-440 (2002).
42. Ashley EA, Powers J, Chen M et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65(1), 73-82 (2005).
43. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur. J. Pharmacol. 553(1-3), 222-228 (2006).
44. Jia YX, Pan CS, Zhang J et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept. 133(1-3), 147-154 (2006).
45. Falcao-PiRes. I, Goncalves N, Henriques-Coelho T, Moreira-Goncalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 296(6), H2007-H2014 (2009).
46. Chen MM, Ashley EA, Deng DX et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108(12), 1432-1439 (2003).
47. Chong KS, Gardner RS, Morton JJ, Ashley EA, Mcdonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 8(4), 355-360 (2006).
48. Goetze JP, Rehfeld JF, Carlsen J et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133(1-3), 134-138 (2006).
49. Miettinen KH, Magga J, Vuolteenaho O et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul. Pept. 140(3), 178-184 (2007).
50. Ashley EA, Chen M, Quertermous T et al. Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof US20050152836 A1(US 10/850,941), (2005). www.google.com/patents
51. Falcao-Pires. I, Goncalves N, Gavina C et al. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment Expert Opin. Ther. Targets 14(3), 231-241 (2010).
52. Ronkainen VP, Ronkainen JJ, Hanninen SL et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 21(8), 1821-1830 (2007).
53. Pchejetski D, Foussal C, Alfarano C et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur. Heart J. 33(18), 2360-2369 (2012).
54. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res. Cardiol. 102(6), 518-528 (2007).
55. Tao J, Zhu W, Li Y et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ERdependent apoptotic pathways in a time-dependent fashion. Am. J. Physiol. Heart Circ. Physiol. 301(4), H1471-H1486 (2011).
56. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30(6), 1144-1152 (2009).
57. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257(1), 79-83 (1999).
58. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J. Endocrinol. 216(1), T17-36 (2013).
59. Fruebis J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA 98(4), 2005-2010 (2001).
60. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem. 277(33), 29359-29362 (2002).
61. Tsao TS, Tomas E, Murrey HE et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J. Biol. Chem. 278(50), 50810-50817 (2003).
62. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J. Biol. Chem. 278(11), 9073-9085 (2003).
63. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278(4), 2461-2468 (2003).
64. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecularweight forms of Acrp30/adiponectin. Proc. Natl Acad. Sci. USA 101(28), 10308-10313 (2004).
65. Ding G, Qin Q, He N et al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J. Mol. Cell Cardiol. 43(1), 73-84 (2007).
66. Fujioka D, Kawabata K, Saito Y et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart Circ. Physiol. 290(6), H2409-H2416 (2006).
67. Pineiro R, Iglesias MJ, Gallego R et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579(23), 5163-5169 (2005).
68. Van De Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism 62(11), 1513-1521 (2013).
69. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7(8), 941-946 (2001).
70. Chow WS, Cheung BM, Tso AW et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 49(6), 1455-1461 (2007).
71. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10(12), 1384-1389 (2004).
72. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46(4), 459-469 (2003).
73. Falcao-PiRes. I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov. Today 17(15-16), 880-889 (2012).
74. Pilz S, Maerz W, Weihrauch G et al. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta 364(1-2), 251-255 (2006).
75. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin. Chim. Acta 344(1-2), 1-12 (2004).
76. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100(25), 2473-2476 (1999).
77. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103(8), 1057-1063 (2001).
78. Ouedraogo R, Gong Y, Berzins B et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J. Clin. Invest. 117(6), 1718-1726 (2007).
79. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285(3), E527-E533 (2003).
80. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105(24), 2893-2898 (2002).
81. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc. Res. 74(1), 11-18 (2007).
82. Kostopoulos CG, Spiroglou SG, Varakis JN, Apostolakis E, Papadaki HH. Adiponectin/T-cadherin and apelin/APJ expression in human arteries and periadventitial fat: implication of local adipokine signaling in atherosclerosis Cardiovasc. Pathol. 23(3), 131-138 (2014).
83. Shibata R, Izumiya Y, Sato K et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell Cardiol. 42(6), 1065-1074 (2007).
84. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press. 13(4), 236-242 (2004).
85. Takahashi T, Yu F, Saegusa S et al. Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int. Heart J. 47(1), 107-123 (2006).
86. Eiras S, Teijeira-Fernandez E, Shamagian LG, Fernandez AL, Vazquez-Boquete A, Gonzalez-Juanatey JR. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine 43(2), 174-180 (2008).
87. Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B, Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J. Hum. Hypertens. 22(12), 856-863 (2008).
88. Ohashi K, Kihara S, Ouchi N et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47(6), 1108-1116 (2006).
89. Tao L, Gao E, Jiao X et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11), 1408-1416 (2007).
90. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994).
91. Wellhoener P, Fruehwald-Schultes B, Kern W et al. Glucose metabolism raTher. than insulin is a main determinant of leptin secretion in humans. J. Clin. Endocrinol. Metab. 85(3), 1267-1271 (2000).
92. Saladin R, De Vos P, Guerre-Millo M et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 377(6549), 527-529 (1995).
93. Escobar-Morreale HF, Escobar Del Rey F, Morreale De Escobar G. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology 138(10), 4485-4488 (1997).
94. Bornstein SR, Licinio J, Tauchnitz R et al. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J. Clin. Endocrinol. Metab. 83(1), 280-283 (1998).
95. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83(7), 1263-1271 (1995).
96. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189(1), 47-60 (2006).
97. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346(8), 570-578 (2002).
98. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334(5), 292-295 (1996).
99. Myers MG Jr, Heymsfield SB, Haft C et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 15(2), 150-156 (2012).
100. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest. 105(12), 1827-1832 (2000).
101. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc. Med. 17(6), 206-211 (2007).
102. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 18(3-4), 313-325 (2007).
103. Quehenberger P, Exner M, Sunder-Plassmann R et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res. 90(6), 711-718 (2002).
104. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin IIand endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J. Pharmacol. Exp. Ther. 315(3), 1075-1084 (2005).
105. Howard JK, Lord GM, Matarese G et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest. 104(8), 1051-1059 (1999).
106. Reyes M, Quintanilla C, Burrows R, Blanco E, Cifuentes M, Gahagan S. Obesity is associated with acute inflammation in a sample of adolescents. Pediatr. Diabetes doi:10.1111/pedi.12129(2014) (Epub ahead of print).
107. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol. Behav. 30, 157-169 (2014).
108. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br. J. Pharmacol. 149(1), 5-13 (2006).
109. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 31(1 Pt 2), 409-414 (1998).
110. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84(10), 3686-3695 (1999).
111. Rodriguez A, Fruhbeck G, Gomez-Ambrosi J et al. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. J. Hypertens. 24(8), 1589-1597 (2006).
112. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest. 115(3), 509-517 (2005).
113. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 47(2), 222-229 (2006).
114. Ren J, Zhu BH, Relling DP, Esberg LB, Ceylan-Isik AF. High-fat diet-induced obesity leads to resistance to leptininduced cardiomyocyte contractile response. Obesity (Silver Spring) 16(11), 2417-2423 (2008).
115. Ricci E, Smallwood S, Chouabe C et al. Electrophysiological characterization of left ventricular myocytes from obese Sprague-Dawley rat. Obesity (Silver Spring) 14(5), 778-786 (2006).
116. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc. Res. 69(3), 716-725 (2006).
117. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307-312 (2001).
118. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr. Protein Pept. Sci. 10(1), 96-107 (2009).
119. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab. 91(7), 2755-2760 (2006).
120. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174(9), 5789-5795 (2005).
121. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem. Biophys. Res. Commun. 334(4), 1092-1101 (2005).
122. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110(21), 3335-3340 (2004).
123. Mu H, Ohashi R, Yan S et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc. Res. 70(1), 146-157 (2006).
124. Rae C, Robertson SA, Taylor JM, Graham A. Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophages. FEBS Lett. 581(25), 4877-4883 (2007).
125. Calabro P, Cirillo P, Limongelli G et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J. Vasc. Res. 48(1), 59-66 (2011).
126. Chen C, Jiang J, Lu JM et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 299(1), H193-H201 (2010).
127. Robertson SA, Rae CJ, Graham A. Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NOdependent pathways. Regul. Pept. 152(1-3), 41-47 (2009).
128. Chemaly ER, Hadri L, Zhang S et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J. Mol. Cell Cardiol. 51(2), 144-155 (2011).
129. Lubos E, Messow CM, Schnabel R et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 193(1), 121-128 (2007).
130. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708), 426-430 (2005).
131. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol. 14(2), 1431-1437 (1994).
132. Rongvaux A, Shea RJ, Mulks MH et al. Pre-B-cell colonyenhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32(11), 3225-3234 (2002).
133. Haider DG, Holzer G, Schaller G et al. The adipokine visfatin is markedly elevated in obese children. J. Pediatr. Gastroenterol. Nutr. 43(4), 548-549 (2006).
134. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91(4), 1578-1581 (2006).
135. Retnakaran R, Youn BS, Liu Y et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a crosssectional study. Clin. Endocrinol. (Oxford) 69(6), 885-893 (2008).
136. Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection Curr. Opin. Pharmacol. 9(2), 202-207 (2009).
137. Chan TF, Chen YL, Lee CH et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig. 13(5), 364-367 (2006).
138. Pagano C, Pilon C, Olivieri M et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J. Clin. Endocrinol. Metab. 91(8), 3165-3170 (2006).
139. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem. 15(18), 1851-1862 (2008).
140. Xie H, Tang SY, Luo XH et al. Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int. 80(3), 201-210 (2007).
141. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115(8), 972-980 (2007).
142. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56(4), 451-458 (2007).
143. Adya R, Tan BK, Chen J, Randeva HS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205(1), 113-119 (2009).
144. Kim SR, Bae SK, Choi KS et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun. 357(1), 150-156 (2007).
145. Park JW, Kim WH, Shin SH et al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochim. Biophys. Acta 1813(5), 763-771 (2011).
146. Pillai VB, Sundaresan NR, Kim G et al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 304(3), H415-H426 (2013).
147. Yu XY, Qiao SB, Guan HS, Liu SW, Meng XM. Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Horm. Metab. Res. 42(7), 507-513 (2010).
148. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J. Cell Mol. Med. 12(4), 1395-1403 (2008).
149. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab. 11(5), 175-180 (2000).
150. Agra RM, Fernandez-Trasancos A, Sierra J, Gonzalez-Juanatey JR, Eiras S. Differential association of S100A9, an inflammatory marker, and p53, a cell cycle marker, expression with epicardial adipocyte size in patients with cardiovascular disease. Inflammation 37(5), 1504-1512 (2014).
151. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274(5291), 1377-1379 (1996).
152. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141(9), 3388-3396 (2000).
153. Furuhashi M, Tuncman G, Gorgun CZ et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447(7147), 959-965 (2007).
154. Tuncman G, Erbay E, Hom X et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl Acad. Sci. USA 103(18), 6970-6975 (2006).
155. Lamounier-Zepter V, Look C, Alvarez J et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ. Res. 105(4), 326-334 (2009).
156. Donato R, Cannon BR, Sorci G et al. Functions of S100 proteins. Curr. Mol. Med. 13(1), 24-57 (2013).
157. Tsoporis JN, Marks A, Haddad A, Dawood F, Liu PP, Parker TG. S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation 111(5), 598-606 (2005).
158. Volkers M, Rohde D, Goodman C, Most P. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J. BioMed. Biotechnol. 2010, 178614 (2010).
159. Yamaguchi N, Chakraborty A, Huang TQ et al. Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. Am. J. Physiol. Heart Circ. Physiol. 305(1), H86-H94 (2013).
160. Most P, Seifert H, Gao E et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114(12), 1258-1268 (2006).
161. Hernandez-Ochoa EO, Prosser BL, Wright NT, Contreras M, Weber DJ, Schneider MF. Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons. Am. J. Physiol. Cell Physiol. 297(4), C955-C970 (2009).
162. Most P, Raake P, Weber C, Katus HA, Pleger ST. S100A1 gene therapy in small and large animals. Methods Mol. Biol. 963, 407-420 (2013).
163. Wang W, Asp ML, Guerrero-Serna G, Metzger JM. Differential effects of S100 proteins A2 and A6 on cardiac Ca cycling and contractile performance. J. Mol. Cell Cardiol. 72C, 117-125 (2014).
164. Tamaki Y, Iwanaga Y, Niizuma S et al. Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts. J. Mol. Cell Cardiol. 57, 72-81 (2013).
165. Wu Y, Li Y, Zhang C et al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertension, 63(6), 1241-1250 (2014).
166. Ehlermann P, Eggers K, Bierhaus A et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc. Diabetol. 5, 6 (2006).